The patent relates to a “Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis”.
Brief outline of the case
The OD decided maintenance according to AR 16 as the claims as granted and AR 1-15 where lacking sufficiency.
The opponent appealed the decision of the OD.